Labat Africa Limited announced its subsidiary, Biodata (Pty) Limited headed by Dr. Shiksha Gallow as the Principal Investigator of the study, has received the Ethics Committee approval to conduct an observational research trial to replace Opioids with Medical Cannabis for Pain Management. The sponsor of the study is Labat Healthcare and is one of the first Medical cannabis research observational trials in South Africa. Biodata is focused on the Cannabis industry and was initially set up as a Holistic Healing Enterprise incorporating Cannabinoid healing. The Company is currently well positioned to commence with formalised Clinical Trials focused on Pain Management and Insomnia. The research conducted by Dr. Gallow on Cannabinoids, Ayurvedic medicine as well as Homeopathic medicines is a significant enhancement to Labat Africa's Nutraceutical and Pharmaceutical offerings. With the growing international trend of opiate addiction and its impact on overdoses, ill-health and crime, with countries worldwide searching desperately for safer alternatives to treat severe and mild pain. The Research study has been accepted as complying to the Ethics Standards for Clinical Research with a new drug based on FDA, ICH, GCP and the declaration of Helsinki guidelines. The study investigates the replacement of opioids with medical cannabis, and would help practitioners understand the effects of cannabinoids for pain management and stress related disorders. Dr. Gallow has received Pharma Ethics approval for this study, making it the first cannabis study receiving ethics approval in SA. This is a large-scale study using Medical Cannabis Real World Evidence (MC-RWE), as 1,000 participants will be recruited using three different sites. Patients pain management while on medical cannabis will be observed and documented, side effects will also be noted as well as drug interactions. The study includes the use of both the cannabis flower and cannabis oil, patients will be recruited once they are eligible for the study according to the inclusion and exclusion criteria set out by Dr. Gallows protocol. There are innumerable benefits that will result from this research and practitioners and researchers alike, are anxiously waiting for this study to go live. Now that the trials have been approved, Dr. Gallow and her team of doctors will begin the recruitment of patients. Dr. Gallows' team includes likeminded practitioners, who understand the benefits of cannabis for medicinal purposes. Her team includes: Dr. Regina Hurley, Dr. Ahmed Jamaloodeen, Dr. Xavagne Fransman and Dr. Omphemetse Mathibe. Other collaborators include Dr. Marian Tupy.